Reply to Cengiz Beyan and Esin Beyan. Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 97(2), 3-4, 2020. - Suppr | 超能文献

相似文献

1

Reply to Cengiz Beyan and Esin Beyan. Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 97(2), 3-4, 2020.

Int J Clin Oncol. 2020 Dec;25(12):2177-2178. doi: 10.1007/s10147-020-01815-6. Epub 2020 Oct 26.

2

Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer.

Int J Clin Oncol. 2020 Dec;25(12):2175-2176. doi: 10.1007/s10147-020-01751-5. Epub 2020 Jul 16.

3

In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".针对Cengiz Beyan和Esin Beyan致编辑的信，信的主题为“能否在入院时通过常规血液检查预测鼻咽癌个体患者的预后？”

Radiother Oncol. 2023 Apr;181:109530. doi: 10.1016/j.radonc.2023.109530. Epub 2023 Feb 10.

4

Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.血小板体积可预测转移性去势抵抗性前列腺癌的治疗特异性结局。

Int J Clin Oncol. 2020 Sep;25(9):1695-1703. doi: 10.1007/s10147-020-01712-y. Epub 2020 Jun 2.

5

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.血小板与淋巴细胞比值和中性粒细胞与淋巴细胞比值在接受阿比特龙或恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者中的预后作用。

Minerva Urol Nephrol. 2021 Dec;73(6):863-865. doi: 10.23736/S2724-6051.21.04814-X.

6

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.未经化疗的转移性去势抵抗性前列腺癌且基线前列腺特异性抗原低的男性患者使用恩扎卢胺与安慰剂治疗的临床结局对比。

J Urol. 2017 Dec;198(6):1324-1332. doi: 10.1016/j.juro.2017.07.071. Epub 2017 Jul 20.

7

Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.揭示中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值在接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者中的预后特征：一项荟萃分析。

Prostate Cancer Prostatic Dis. 2020 Jun;23(2):220-231. doi: 10.1038/s41391-020-0209-3. Epub 2020 Feb 7.

8

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.回复：多西他赛和阿比特龙治疗转移性去势抵抗性前列腺癌失败后使用恩杂鲁胺的情况

Eur J Cancer. 2014 Mar;50(5):1042-3. doi: 10.1016/j.ejca.2013.12.016. Epub 2014 Jan 13.

9

Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.18F-胆碱 PET/CT 代谢参数对接受阿比特龙或恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者的预后价值。

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6.

10

Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?: Estimating the Clinical Utility of Blood-based AR-V7 Testing in Prostate Cancer.

Eur Urol. 2017 Dec;72(6):e170-e171. doi: 10.1016/j.eururo.2017.06.032. Epub 2017 Jul 8.

引用本文的文献

1

Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma.当代全国范围内II/III期直肠腺癌术前治疗后的手术模式。

World J Gastrointest Oncol. 2022 Jun 15;14(6):1148-1161. doi: 10.4251/wjgo.v14.i6.1148.

2

Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer.

Int J Clin Oncol. 2020 Dec;25(12):2175-2176. doi: 10.1007/s10147-020-01751-5. Epub 2020 Jul 16.

本文引用的文献

1

Plateletcrit may not be an index for predicting liver fibrosis in patients with chronic hepatitis B.血小板压积可能不是预测慢性乙型肝炎患者肝纤维化的指标。

J Viral Hepat. 2020 Jul;27(7):757. doi: 10.1111/jvh.13289. Epub 2020 Apr 15.

2

Mean platelet volume to lymphocyte ratio may not be a marker for overall survival in non-metastatic clear cell renal cell carcinoma patients treated with nephrectomy.平均血小板体积与淋巴细胞比值可能不是接受肾切除术治疗的非转移性透明细胞肾细胞癌患者总生存的标志物。

Int Urol Nephrol. 2020 Aug;52(8):1453-1454. doi: 10.1007/s11255-020-02436-8. Epub 2020 Mar 5.

3

Platelet indices may not be associated with diagnosis and prognosis of gastrointestinal bleeding.